Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19024815 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL10756784 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL15650301 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL2635952 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL5033212 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL15649718 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL317272 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL2635949 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL21853572 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL19024591 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | claimed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | claimed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | claimed |
| EP-4662197-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4433093-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024165426-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2024-08-15 | — | — | WO | disclosed |
| EP-4414360-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2024-08-14 | — | — | EP | disclosed |
| CN-118488855-A | Solid composition comprising peptide or protein and acylated amino acid | 阿道恰公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4299057-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023084118-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2023-05-19 | — | — | WO | disclosed |
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | BAD, BAX, BCL2 | ACE 3869/4885ACE2 3998/4885L3MBTL1 2909/4885 |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPPA, BCAT1, ANPEP | ACE 684/4885ACE2 991/4885L3MBTL1 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.